Know Cancer

or
forgot password

SUPPORTIVE-EXPRESSIVE GROUP THERAPY FOR MEN WITH PRIMARY PROSTATE CANCER


N/A
N/A
N/A
Not Enrolling
Male
Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment

Thank you

Trial Information

SUPPORTIVE-EXPRESSIVE GROUP THERAPY FOR MEN WITH PRIMARY PROSTATE CANCER


OBJECTIVES:

- Determine the feasibility of providing group support, and evaluate the effect of
supportive-expressive group therapy vs. written educational material on the
psychological health and quality of life of men with stage I/II prostate cancer.

OUTLINE: Patients are stratified by prior hormonal therapy.

Patients continue standard oncologic treatment concurrently with supportive-expressive group
therapy.

Supportive-expressive group therapy consists of twelve 90-minute weekly meetings with 8-12
members and 2 cotherapists and is based on the following themes: building bonds, expressing
emotions, detoxifying dying, taking time to prioritize and set realistic goals, fortifying
families, and dealing with doctors. Each session commences with a brief stress reduction
exercise and ends with a brief cognitive restructuring imagery exercise. The main portion of
the meeting emphasizes providing an environment in which patients can share their concerns,
feelings, and thoughts openly and honestly. The role of the cotherapist is to facilitate
expression of patients' concerns, offer empathy, and continue to encourage patients to
express their feelings and thoughts.

Quality-of-life questionnaires are filled out at 3 and 6 months and then every 6 months for
a total of 2 years.

PROJECTED ACCRUAL: Approximately 480 patients (including an estimated 53 minority patients)
will be entered in this multicenter study.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Biopsy-proven prostate cancer diagnosed within 1 year prior to entry

- Clinical stage I/II (T1b-c or T2, N0 or Nx, M0) disease

- Pathologic local upstaging (e.g., to T3) allowed

- No Nx disease if pathologic or partial pathologic (e.g., lymph node
biopsy or dissection) staging performed

- No major psychiatric illness requiring hospitalization or medication other than
depression or anxiety for less than 1 year

- No second malignancy within 10 years except nonmelanomatous skin cancer

- Clinical follow-up by a urologist, medical oncologist, or radiation therapist
required at least semi-annually

PATIENT CHARACTERISTICS:

Age

- Not specified

Performance status

- Not specified

Life expectancy

- Not specified

Hematopoietic

- Not specified

Hepatic

- Not specified

Renal

- Not specified

Other

- See Disease Characteristics

PRIOR CONCURRENT THERAPY:

Biologic therapy

- Not specified

Chemotherapy

- Not specified

Endocrine therapy

- Not specified

Radiotherapy

- Not specified

Surgery

- Not specified

Type of Study:

Interventional

Study Design:

N/A

Principal Investigator

Gary R. Morrow, PhD, MS

Investigator Role:

Study Chair

Investigator Affiliation:

James P. Wilmot Cancer Center

Authority:

United States: Federal Government

Study ID:

CDR0000065087

NCT ID:

NCT00002848

Start Date:

April 1997

Completion Date:

September 2004

Related Keywords:

  • Prostate Cancer
  • Psychosocial Effects of Cancer and Its Treatment
  • stage I prostate cancer
  • stage IIB prostate cancer
  • stage IIA prostate cancer
  • psychosocial effects of cancer and its treatment
  • Prostatic Neoplasms

Name

Location

CCOP - WichitaWichita, Kansas  67214-3882
CCOP - KalamazooKalamazoo, Michigan  49007-3731
CCOP - ColumbusColumbus, Ohio  43206
CCOP - Western Regional, ArizonaPhoenix, Arizona  85006-2726
CCOP - NorthwestTacoma, Washington  98405-0986
Stanford Cancer Center at Stanford University Medical CenterStanford, California  94305
James P. Wilmot Cancer Center at University of Rochester Medical CenterRochester, New York  14642